Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, United States.
Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, United States.
Contraception. 2020 Sep;102(3):168-173. doi: 10.1016/j.contraception.2020.05.004. Epub 2020 May 19.
To evaluate serum estradiol (E2) concentrations during use of 90-day contraceptive vaginal rings releasing E2 75, 100, or 200 mcg/day and segesterone acetate (SA) 200 mcg/day to identify a dose that avoids hypoestrogenism.
We conducted a multicenter dose-finding study in healthy, reproductive-aged women with regular cycles with sequential enrollment to increasing E2 dose groups. We evaluated serum E2 concentrations twice weekly for the primary outcome of median E2 concentrations throughout initial 30-day use (target ≥40 pg/mL). In an optional 2-cycle extension substudy, we randomized participants to 2- or 4-day ring-free intervals per 30-day cycle to evaluate bleeding and spotting based on daily diary information.
Sixty-five participants enrolled in E2 75 (n = 22), 100 (n = 21), and 200 (n = 22) mcg/day groups; 35 participated in the substudy. Median serum E2 concentrations in 75 and 100 mcg/day groups were <40 pg/mL. In the 200 mcg/day group, median E2 concentrations peaked on days 4-5 of CVR use at 194 pg/mL (range 114-312 pg/mL) and remained >40 pg/mL throughout 30 days; E2 concentrations were 37 pg/mL (range 28-62 pg/mL) on days 88-90 (n = 11). Among the E2 200 mcg/day substudy participants, all had withdrawal bleeding following ring removal. The 2-day ring-free interval group reported zero median unscheduled bleeding and two (range 0-16) and three (range 0-19) unscheduled spotting days in extension cycles 1 and 2, respectively. The 4-day ring-free interval group reported zero median unscheduled bleeding or spotting days.
Estradiol concentrations with rings releasing E2 200 mcg/day and SA 200 mcg/day avoid hypoestrogenism over 30-day use.
A 90-day contraceptive vaginal ring releasing estradiol 200 mcg/day and segesterone acetate 200 mcg/day achieves estradiol concentrations that should avoid hypoestrogenism and effectively suppresses ovulation.
评估每日释放雌二醇 75、100 或 200mcg 和醋酸赛普酮 200mcg 的 90 天避孕阴道环使用期间的血清雌二醇(E2)浓度,以确定避免雌激素不足的剂量。
我们在具有规律周期的健康育龄妇女中进行了一项多中心剂量发现研究,这些妇女连续入组至 E2 剂量递增组。我们每周两次评估血清 E2 浓度两次,以评估初始 30 天使用期间的中位数 E2 浓度(目标值≥40pg/ml),这是主要结局。在可选的 2 个周期扩展子研究中,我们将参与者随机分配至每 30 天周期的 2 或 4 天无环间隔,根据每日日记信息评估出血和点滴出血情况。
65 名参与者入组至雌二醇 75mcg(n=22)、100mcg(n=21)和 200mcg(n=22)组;35 名参与者参加了子研究。75mcg 和 100mcg 组的中位血清 E2 浓度<40pg/ml。在 200mcg 组中,CVR 使用第 4-5 天 E2 浓度达到 194pg/ml(范围 114-312pg/ml),30 天内 E2 浓度保持>40pg/ml;在第 88-90 天(n=11)E2 浓度为 37pg/ml(范围 28-62pg/ml)。在雌二醇 200mcg 组的子研究参与者中,所有参与者在取出戒指后均有撤退性出血。在 2 天无环间隔组中,在扩展周期 1 和 2 中分别报告了 0 个中位非计划性出血和 2 个(范围 0-16)和 3 个(范围 0-19)非计划性点状出血天数。4 天无环间隔组报告 0 个中位非计划性出血或点状出血天数。
每日释放雌二醇 200mcg 和醋酸赛普酮 200mcg 的避孕阴道环使用 30 天可避免雌激素不足。
90 天避孕阴道环释放雌二醇 200mcg 和醋酸赛普酮 200mcg 可达到避免雌激素不足并有效抑制排卵的雌二醇浓度。